O- Or S- Glycosides Patents (Class 536/4.1)
  • Patent number: 10160787
    Abstract: Described are ?-PNA monomers, methodology for synthesizing them, and methodology for synthesizing PNA oligomers that incorporate them.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: December 25, 2018
    Assignee: CARNEGIE MELLON UNIVERSITY
    Inventors: Danith H. Ly, Srinivas Rapireddy, Bichismita Sahu
  • Patent number: 10144754
    Abstract: The invention provides a nucleotide or nucleoside having a base attached to a detectable label via a cleavable linker, characterized in that the cleavable linker contains a moiety selected from the group comprising: Formula (I) (wherein X is selected from the group comprising O, S, NH and NQ wherein Q is a C1-10 substituted or unsubstituted alkyl group, Y is selected from the group comprising O, S, NH and N(allyl), T is hydrogen or a C1-10 substituted or unsubstituted alkyl group and * indicates where the moiety is connected to the remainder of the nucleotide or nucleoside).
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: December 4, 2018
    Assignee: Illumina Cambridge Limited
    Inventors: Xiaohai Liu, John Milton, Silke Ruediger
  • Patent number: 9879012
    Abstract: Click nucleic acid monomers and polymers containing such monomers are disclosed. The click nucleic acid monomers include an optionally protected thiol moiety, an optionally protected thiol-click acceptor moiety, and an optionally protected nucleobase (NB), which in some examples is an A, G, T, U, or C nucleobase. In some examples, the click nucleic acid monomer includes a N-vinyl thiol acetamide (VTA) backbone. In other examples the click nucleic acid monomer includes a N-vinyl thiol ethylamine (VTE) backbone. Methods of using such polymers, for example in place of naturally occurring nucleic acid polymer applications, such as DNA or RNA, and synthetic nucleic acid polymer applications, such as PNA or morpholino nucleic acids, are also disclosed.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: January 30, 2018
    Assignee: REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Christopher N. Bowman, Christopher J. Kloxin, Weixian Xi
  • Patent number: 9809614
    Abstract: Cells incorporating a synthetic molecule construct of the structure F—S1—S2-L where: F—S1 is an aminoalkylglycoside where F is a mono-, di-, tri- or oligo-saccharide and S1 is 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, or 5-aminopentyl; S2 is —CO(CH2)2CO—, —CO(CH2)3CO—, —CO(CH2)4CO— or —CO(CH2)5CO—; and L is phosphatidylethanolamine.
    Type: Grant
    Filed: May 30, 2016
    Date of Patent: November 7, 2017
    Assignee: KODE BIOTECH LIMITED
    Inventors: Nicolai Bovin, Lissa Gilliver, Stephen Henry, Elena Korchagina
  • Patent number: 9598455
    Abstract: Disclosed are modified thymine bases that provide enhanced base-pairing affinity for adenine or 2,6-diaminopurine bases in polynucleotide hybridization complexes. Also disclosed are polynucleotide oligomers, polynucleotide hybridization complexes that comprise such modified thymine bases. Also disclosed are various methods of use. For example, in some embodiments, modified polynucleotide oligomers disclosed herein can be used as primers and probes for nucleic acid amplification and/or detection.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: March 21, 2017
    Assignee: Cepheid
    Inventors: Alexander A. Gall, Sergey G. Lokhov, Mikhail A. Podyminogin, Ekaterina V. Viazovkina, Kevin Patrick Lund
  • Patent number: 9598456
    Abstract: Disclosed are modified cytosine bases that provide enhanced base-pairing affinity for guanine bases in polynucleotide hybridization complexes. Also disclosed are polynucleotide oligomers, polynucleotide hybridization complexes that comprise such modified cytosine bases. Also disclosed are various methods of use. For example, in some embodiments, modified polynucleotide oligomers disclosed herein can be used as primers and probes for nucleic acid amplification and/or detection.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: March 21, 2017
    Assignee: Cepheid
    Inventors: Alexander A. Gall, Sergey G. Lokhov, Mikhail A. Podyminogin, Ekaterina V. Viazovkina, Kevin Patrick Lund
  • Patent number: 9593373
    Abstract: Some embodiments described herein relate to modified nucleotide and nucleoside molecules with novel 3?-hydroxy protecting groups. Also provided herein are methods to prepare such modified nucleotide and nucleoside molecules and sequencing by synthesis processes using such modified nucleotide and nucleoside molecules.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: March 14, 2017
    Assignee: Illumina Cambridge Limited
    Inventors: Xiaohai Liu, Xiaolin Wu, Geoffrey Paul Smith
  • Patent number: 9551029
    Abstract: Extended rhodamine compounds exhibiting favorable fluorescence characteristics having the structure are disclosed. In addition, novel intermediates for synthesis of these dyes are disclosed, such intermediates having the structure In addition, methods of making and using the dyes as fluorescent labels are disclosed.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: January 24, 2017
    Assignee: APPLIED BIOSYSTEMS, LLC
    Inventors: Joe Y. L. Lam, Scott C. Benson, Steven M. Menchen
  • Patent number: 9365603
    Abstract: [Problem] To impart significantly improved myo-inositol producing capability, suitable for use in recombinant DNA techniques and synthetic biology methods, to a host microorganism that does not possess an endogenous myo-inositol biosynthesis pathway, such as Escherichia coli. [Solution] Inositol monophosphatase activity is strengthened in a transformant obtained by introducing a myo-inositol biosynthesis pathway into a host microorganism that does not possess an endogenous myo-inositol biosynthesis pathway.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: June 14, 2016
    Assignee: Asahi Kasei Chemicals Corporation
    Inventors: Kazunobu Konishi, Shinichi Imazu, Mayumi Sato
  • Patent number: 9353349
    Abstract: Cells incorporating a synthetic molecule construct of the structure F—S1-S2-L where: F—S1 is an aminoalkylglycoside where F is a mono-, di-, tri- or oligo-saccharide and S1 is 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, or 5-aminopentyl; S2 is —CO(CH2)2CO—, —CO(CH2)3CO—, —CO(CH2)4CO— or —CO(CH2)5CO—; and L is phosphatidylethanolamine.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: May 31, 2016
    Assignee: KODE BIOTECH LIMITED
    Inventors: Nicolai Bovin, Lissa Gilliver, Stephen Henry, Elena Korchagina
  • Patent number: 9321799
    Abstract: The present invention provides modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides and analogs thereof that are useful for incorporation at the terminus of an oligomeric compound. Such oligomeric compounds can also be included in a double stranded composition. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: April 26, 2016
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Patent number: 9310366
    Abstract: The present invention presents the isolation, characterization and synthesis of oligosaccharides of Bacillus anthracis. Also presented are antibodies that bind to such saccharide moieties and various methods of use for such saccharide moieties and antibodies.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: April 12, 2016
    Assignees: University of Georgia Research Foundation, Inc., The United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Russell W. Carlson, Geert-Jan Boons, Therese Buskas, Elmar Kannenberg, Alok Mehta, Elke Saile, Conrad Quinn, Patricia Wilkins, Mahalakshmi Vasan, Margreet A. Wolfert
  • Patent number: 9297042
    Abstract: This invention provides a nucleotide analog comprising (i) a base selected from the group consisting of adenine, guanine, cytosine, thymine and uracil, (ii) a deoxyribose, (iii) an allyl moiety bound to the 3?-oxygen of the deoxyribose and (iv) a fluorophore bound to the base via an allyl linker, and methods of nucleic acid sequencing employing the nucleotide analog.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: March 29, 2016
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Jingyue Ju, Lanrong Bi, Dae Hyun Kim, Qinglin Meng
  • Patent number: 9290531
    Abstract: The present invention relates to synthetic lipoteicoic acid (LTA) mimetics which are useful as vaccine components for therapy and/or prophylaxis of bacterial infection.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: March 22, 2016
    Assignee: UNIVERSITÄTSKLINIKUM FREIBURG
    Inventors: Johannes Huebner, Andrea Huebner-Kropec, Jeroen Dirk Cornelis Codée, Gijsbert Arie Van Der Marel, Wouter Frederick Johan Hogendorf
  • Patent number: 9285319
    Abstract: It is an object of the present invention to provide quenching or fluorescent nucleic acid base analogs and applications thereof. The quencher of the present invention has a 2-nitropyrrole structure represented by Formula I: [Formula 1] (in Formula I, R1 and R2 are groups independently selected from the group consisting of: ribose and deoxyribose; hydrogen, hydroxyl and SH groups, and halogens; substituted or unsubstituted alkyl, alkenyl, and alkynyl groups each having 2 to 10 carbon atoms; one or more five-membered heterocyclic rings, one or more six-membered heterocyclic rings, and one or more fused heterocyclic rings, these heterocylic rings containing nitrogen or sulfur, and one or more aromatic rings; sugars, sugar chains, amino acids, and peptides; and fluorescent molecules linked via linkers).
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: March 15, 2016
    Assignees: RIKEN, TagCyx Biotechnologies
    Inventors: Ichiro Hirao, Michiko Hirao, Shigeyuki Yokoyama, Tsuneo Mitsui, Rie Yamashige
  • Patent number: 9259710
    Abstract: A separation material includes a saccharide bound via a linker to a matrix for enabling the separation from a liquid of substances that selectively bind to saccharide moieties. A method for preparing the material, a method for separating from a liquid substances that selective bind to saccharides, and a device including the separation material are also disclosed.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: February 16, 2016
    Assignee: Gambro Lunia AB
    Inventors: Martin Rempfer, Wolfgang Freudemann, Cornelia Winz, Ralf Flieg, Markus Storr, Manuela Klotz, Sandra Homeyer, Torsten Knoer
  • Patent number: 9193758
    Abstract: The present invention relates to ?-PNA monomers according to Formula I where substituent groups R1, R2, R3, R4, R5, R6, B and P are defined as set forth in the specification. The invention also provides methodology for synthesizing compounds according to Formula I and methodology for synthesizing PNA oligomers that incorporate one or more Formula I monomers.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: November 24, 2015
    Assignee: Carnegie Mellon University Center for Technology Transfer & Enterprise
    Inventors: Danith H. Ly, Srinivas Rapireddy, Bichismita Sahu
  • Patent number: 9150896
    Abstract: Provided herein is a method of amplifying nucleic acids using a plurality of modified nucleotides one or more of the nucleotides comprising a 3? blocking group. Also provided is a method of amplifying nucleic acids using oligonucleotide primers one or both of the primers comprising a 3? blocking group on one or more of the nucleotides of the primers.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: October 6, 2015
    Assignee: Illumina, Inc.
    Inventors: Cheng-Yao Chen, Gothami Padmabandu
  • Patent number: 9121060
    Abstract: The invention provides modified nucleotide or nucleoside molecule comprising a purine or pyrimidine base and a ribose or deoxyribose sugar moiety having a removable 3?-OH blocking group covalently attached thereto, such that the 3? carbon atom has attached a group of the structure —O—Z wherein Z is any of —C(R?)2-O—R?, —C(R?)2-N(R?)2, —C(R?)2-N(H)R?, —C(R?)2-S—R? and —C(R?)2-F, wherein each R? is or is part of a removable protecting group; each R? is independently a hydrogen atom, an alkyl, substituted alkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclic, acyl, cyano, alkoxy, aryloxy, heteroaryloxy or amido group, or a detectable label attached through a linking group; or (R?)2 represents an alkylidene group of formula ?C(R??)2 wherein each R?? may be the same or different and is selected from the group comprising hydrogen and halogen atoms and alkyl groups; and wherein said molecule may be reacted to yield an intermediate in which each R? is exchanged for H or, where Z is —C(R?)2-F, the F is ex
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: September 1, 2015
    Assignee: Illumina Cambridge Limited
    Inventors: John Milton, Xiaolin Wu, Mark Smith, Joseph Brennan, Colin Barnes, Xiaohai Liu, Silke Ruediger
  • Patent number: 9101162
    Abstract: The present invention provides a process for preparation of highly purified mogrosides mixture from low purity mogrosides mixture.
    Type: Grant
    Filed: August 29, 2011
    Date of Patent: August 11, 2015
    Assignee: PureCircle Sdn Bhd
    Inventor: Avetik Markosyan
  • Patent number: 9045507
    Abstract: The design, synthesis, and utilization of a novel coumarin-based amino acid and its fluorinated derivatives for use in enzyme activity and substrate specificity assays are described. The synthesis is both facile and high-yielding and allows for the production of a highly fluorescent phosphorylated amino acid that can be incorporated into peptides using standard SPPS techniques. The resultant substrates are efficiently hydrolyzed by PTPs and exhibit a large increase in fluorescence upon hydrolysis. Fluorinated CAP derivatives have utility as fluorogenic enzyme substrates. CAP and its derivatives can be incorporated into combinatorial peptide libraries for assaying enzyme substrate specificities.
    Type: Grant
    Filed: July 27, 2006
    Date of Patent: June 2, 2015
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Amy M. Barrios, Sayantan Mitra
  • Publication number: 20150140576
    Abstract: The present invention describes glycans, which are specifically expressed by certain cancer cells, tumours and other malignant tissues. The present invention describes methods to detect cancer specific glycans as well as methods for the production of reagents binding to said glycans. The invention is also directed to the use of said glycans and reagents binding to them for the diagnostics of cancer and malignancies. Furthermore, the invention is directed to the use of said glycans and reagents binding to them for the treatment of cancer and malignancies. Moreover, the present invention comprises efficient methods to differentiate between malignant and benign tumors by analyzing glycan structures.
    Type: Application
    Filed: October 24, 2014
    Publication date: May 21, 2015
    Applicant: GLYKOS FINLAND OY
    Inventors: Tero SATOMAA, Jari NATUNEN, Annamari HEISKANEN, Anne OLONEN, Juhani SAARINEN, Noora SALOVUORI, Jari HELIN
  • Publication number: 20150140610
    Abstract: A process for making the compound of Formula I utilizes the starting compound, together with sulfilimine and sulfoxide process steps later on.
    Type: Application
    Filed: May 22, 2013
    Publication date: May 21, 2015
    Inventors: Adrian Ortiz, Tamas Benkovics, Zhongping Shi, Prashant P. Deshpande, Zhiwei Guo, David R. Kronenthal, Chris Sfouggatakis
  • Patent number: 9034834
    Abstract: The disclosure provides an oral antiviral supplement composition comprising a lysine, an ascorbic compound, a flavonoid glycoside, a threonine, and a pyridoxine. The disclosure also provides a method of reducing viral replication in a cell comprising treating a virus-infected cell with a composition of the disclosure. The disclosure further provides a method for the treatment and prophylaxis of a viral infection in a patient comprising administering a composition of the disclosure.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: May 19, 2015
    Assignee: Vymedic, LLC
    Inventors: Kenneth E. Phillips, Cynthia A. Winning
  • Publication number: 20150133647
    Abstract: The application discloses a method for producing anomerically protected glycosidic oligosaccharide derivatives comprising the step of culturing, in a culture medium containing an anomerically protected lactose acceptor, a genetically modified cell having a recombinant gene that encodes a glycosyl transferase that can transfer a glycosyl residue of an activated sugar nucleotide to said lactose acceptor. The application further discloses a method for producing an oligosaccharide comprising the steps of: (a) culturing, in a culture medium containing an anomerically protected lactose acceptor, a genetically modified cell having a recombinant gene that encodes a glycosyl transferase that can transfer a glycosyl residue of an activated sugar nucleotide to said lactose acceptor to produce an anomerically protected glycosidic oligosaccharide derivative, then (b) removing/deprotecting the anomeric protective group.
    Type: Application
    Filed: June 7, 2013
    Publication date: May 14, 2015
    Applicant: Glycom A/S
    Inventors: Pauline Peltier-Pain, Gyula Dekany, Rémy Dureau, Christian Risinger, Markus Hederos, Elise Champion
  • Patent number: 9012413
    Abstract: The invention relates to FGF receptor-activating N-acyl octasaccharides having Formula (I), wherein: R1 is an O-alkyl group optionally replaced by one or more aryl or cycloalkyl groups, R2 is an OSO3? or hydroxyl group, R3 is an alkyl, cycloalkyl, or alkyl-cycloalkyl group, R4 is a disaccharide having Formula (II), R6 is a disaccharide having Formula (III), and R8 is a disaccharide having Formula (IV), where R5, R7, and R9 are OSO3? or hydroxyl groups. The invention further relates to the preparation of said octasaccharides and to the therapeutic use thereof.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: April 21, 2015
    Assignee: Sanofi
    Inventors: Pierre Alexandre Driguez, Philippe Duchaussoy, Pierre Fons, Corentin Herbert, Gilbert Lassalle
  • Patent number: 8993740
    Abstract: The present invention relates to a method for preparation of the tetrasaccharide lacto-N-neotetraose (LNnt, formula (I)) especially in large scale, as well as intermediates in the synthesis, a new crystal form (polymorph) of LNnt, and the use thereof in pharmaceutical or nutritional compositions.
    Type: Grant
    Filed: February 21, 2011
    Date of Patent: March 31, 2015
    Assignee: Glycom A/S
    Inventors: István Bajza, Gyula Dekany, Károly Ágoston, Ignacio Figuero-Pérez, Julien Boutet, Markus Hederos, Ferenc Horváth, Piroska Kovács-Pénzes, Lars Kröger, Christoph Röhrig, Andreas Schroven, Ioannis Vrasidas, Péter Trinka, László Kalmár, Irme Kovács, Sándor Demkó, Ágnes Ágoston, Christian Risinger
  • Patent number: 8993738
    Abstract: The present invention provides modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides and analogs thereof that are useful for incorporation at the terminus of an oligomeric compound. Such oligomeric compounds can also be included in a double stranded composition. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: March 31, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Patent number: 8993737
    Abstract: In various embodiments, the present invention provides fluorescent dyes that are linked to another species through an amino acid or peptide linker. In an exemplary embodiment, the dye is linked to a polyphosphate nucleic acid through an amino acid or peptide linker. These conjugates find use in single molecule DNA sequencing and other applications. In various embodiments, the dye moiety is a cyanine dye. Cyanine dyes that are highly charged, such as those including multiple sulfonate, alkylsulfonate, carboxylate and/or alkylcarboxylate moieties are examples of cyanine dyes of use in the compounds of the invention.
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: March 31, 2015
    Assignee: Pacific Biosciences, Inc.
    Inventor: Gene Shen
  • Patent number: 8987216
    Abstract: The invention relates to polysulfated glycosides of formula (I), the pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions containing these compounds as active ingredients. Furthermore the invention provides a method of preventing, treating or alleviating the symptoms of acute and chronic inflammatory disorders of the airways of mammals—including asthma and asthma-related pathologies.
    Type: Grant
    Filed: January 25, 2011
    Date of Patent: March 24, 2015
    Assignees: Teva Hungary Pharmaceutical Marketing Private Limited Company, Teva Hungary Ltd.
    Inventors: János Kuszmann, István Kurucz, Gábor Medgyes, Nicholas Bodor
  • Patent number: 8980558
    Abstract: The present invention provides compositions, methods and kits for use in the detection of small RNA sequences, which allow for rapid and robust amplification and detection. The methods provide improved sensitivity and efficiency in the amplification-based detection of small RNA sequences by incorporating one or more base-modified duplex-stabilizing dNTPs during reverse transcription and/or amplification.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: March 17, 2015
    Inventor: Igor Vassily Kutyavin
  • Patent number: 8969535
    Abstract: Provided are novel nucleotides, nucleoside, and their derivatives described herein, that can be used in DNA sequencing technology and other types of DNA analysis. In one embodiment, the nucleotide or nucleoside with an unprotected 3?-OH group is derivatized at the nucleobase to include a fluorescent dye attached via a linker to a photocleavable terminating group. The photocleavable-fluorescent group is designed to terminate DNA synthesis as well as be cleaved so that DNA oligomers can be sequenced efficiently in a parallel format. The design of such rapidly cleavable fluorescent groups on nucleotides and nucleosides can enhance the speed and accuracy of sequencing of large oligomers of DNA in parallel, to allow rapid whole genome sequencing, and the identification of polymorphisms and other valuable genetic information, as well as allowing further manipulation and analysis of nucleic acid molecules in their native state following cleavage of the fluorescent group.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: March 3, 2015
    Assignee: Lasergen, Inc.
    Inventors: Weidong Wu, Vladislav A. Litosh, Brian P. Stupi, Michael L. Metzker
  • Patent number: 8962573
    Abstract: The invention relates to conjugates of products of interest including glycoproteins, nanoparticles, and imaging agents and of compounds of the general formula (1): that target the cation-independent mannose 6-phosphate receptor with a high affinity. The invention also relates to their applications, for instance in enzyme replacement therapies.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: February 24, 2015
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Centre National de la Recherche Scientifique—CNRS, Universite de Montpellier 1, Universite de Montpellier 2 Sciences et Techniques
    Inventors: Marcel Garcia, Alain Morere, Magali Gary-Bobo, Martine Cerutti, Khaled El Cheikh, Ilaria Basile, Philippe Nirde
  • Patent number: 8962578
    Abstract: The invention relates to novel fungicidally active compound combinations of 2?-cyano-3,4-dichloroisothiazole-5-carboxanilide and active compounds listed in the disclosure.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: February 24, 2015
    Assignee: Bayer CropScience AG
    Inventors: Peter Dahmen, Ulrike Wachendorff-Neumann, Rolf Pontzen, Lutz Assmann, Haruko Sawada
  • Publication number: 20150031630
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Application
    Filed: May 17, 2012
    Publication date: January 29, 2015
    Inventor: John J. Nestor
  • Patent number: 8940879
    Abstract: To provide a functional molecule including a modified nucleotide unit having a substituent introduced to a base thereof, wherein the substituent is removably introduced to the base; a functional molecule synthesizing amidite that has a substituent removably introduced to its base and that is used for the manufacture of the functional molecule; and a target substance analysis method including: preparing a random pool of functional molecules using a functional molecule synthesizing amidite; screening a functional molecule having affinity for a target substance from the random pool; amplifying the functional molecules having affinity for the target substance, wherein the method further comprises, prior to the amplification step, removing a substituent from the functional molecule having affinity for the target substance.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: January 27, 2015
    Assignee: Apta Biosciences Ltd.
    Inventors: Tsuyoshi Fujihara, Shozo Fujita
  • Publication number: 20150025030
    Abstract: A hydroxysafflor yellow A sodium compound as shown in a formula (I) and preparation as well as medicinal application thereof are provided. According to the present invention, the safflower is utilized as a raw material. A monomer pharmaceutical compound, the hydroxysafflor yellow A sodium, is obtained by sufficient processes, and a purity thereof is surely above 98.5%. Therefore, the hydroxysafflor yellow A sodium is a monomer compound, which is safer, more effective, more stable and more controllable than hydroxysafflor yellow A, for treating blood circulation disorders such as platelet aggregation, coronary heart disease, angina pectoris and acute cerebral ischemia. Furthermore, the hydroxysafflor yellow A sodium has sufficient solubility and human tolerance.
    Type: Application
    Filed: June 8, 2013
    Publication date: January 22, 2015
    Applicant: ZHEJIANG YONGNING PHARMACEUTICAL CO LTD
    Inventors: Fengqi Ye, Ben Cai, Min Lu, Yongling Chen
  • Publication number: 20150025026
    Abstract: Campylobacter are the commonest reported bacterial causes of gastroenteritis in the UK and industrialized worlds. This invention relates to a method of preventing or reducing the colonisation of the gastrointestinal tract of an animal with Campylobacter. Accordingly, the present invention provides a method for disinfection of an animal comprising administering to said animal at least one compound that binds to MOMP or FlaA of Campylobacter in an effective amount to reduce the number of Campylobacter present in the gastrointestinal tract of said animal. The present invention also provides a method of preventing or reducing transmission of Campylobacter from one animal to another.
    Type: Application
    Filed: February 15, 2013
    Publication date: January 22, 2015
    Inventors: Jafar Mahdavi, Dlawer Ala'Aldeen
  • Patent number: 8937167
    Abstract: The present invention encompasses compounds and methods for treating urinary tract infections.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: January 20, 2015
    Assignee: Washington University
    Inventors: James W. Janetka, Zhenfu Han, Scott Hultgren, Jerome S. Pinkner, Corinne Cusumano
  • Patent number: 8927698
    Abstract: The present invention relates to an improved synthesis of a trisaccharide of the formula, novel intermediates used in the synthesis and the preparation of the intermediates.
    Type: Grant
    Filed: April 7, 2010
    Date of Patent: January 6, 2015
    Assignee: Glycom A/S
    Inventors: Gyula Dékany, Istvan Bajza, Julien Boutet, Ignacio Pérez Figueroa, Markus Hederos, Ferenc Horvath, Piroska Kovács-Pénzes, Lars Kröger, Johan Olsson, Christoph Röhrig, Andreas Schroven, Ioannis Vrasidas
  • Patent number: 8927506
    Abstract: Novel compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are provided herein.
    Type: Grant
    Filed: June 25, 2009
    Date of Patent: January 6, 2015
    Assignee: Board of Regents, The University of Texas System
    Inventors: Waldemar Priebe, Marcin Cybulski, Izabela Fokt, Stanislaw Skora, Charles Conrad, Timothy Madden
  • Patent number: 8927497
    Abstract: A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: January 6, 2015
    Assignee: Aegis Therapeutics, LLC.
    Inventor: Edward T. Maggio
  • Publication number: 20150004110
    Abstract: The 1-aryl-2-aryloxyethane compounds of Formula 1 in which n and m are zero or equal to 1, provided that n+m=1, R1 and R2 in particular representing hydrogen atoms, R3 and R4 in particular representing hydrogen atoms, halogen atoms, hydroxy or alkoxy groups, and R5 in particular representing hydrogen atoms, hydroxy, alkyl, alkoxy, amino or nitro groups, in cosmetic compositions intended for anti-ageing and/or depigmenting and/or anti-inflammatory and/or wound-healing care.
    Type: Application
    Filed: December 18, 2012
    Publication date: January 1, 2015
    Applicant: DIVERCHIM
    Inventors: Natacha Frison, Benoit Folleas, Jean-Louis Brayer, Florence Wafflart
  • Patent number: 8921532
    Abstract: The present invention provides labeled phospholink, nucleotides that can be used in place of naturally occurring nucleotide triphosphates or other analogs in template directed nucleic acid synthesis reactions and other nucleic acid reactions and various analyses based thereon, including DNA sequencing, single base identification, hybridization assays, and others.
    Type: Grant
    Filed: October 7, 2013
    Date of Patent: December 30, 2014
    Assignee: Pacific Biosciences of California, Inc.
    Inventor: Jonas Korlach
  • Publication number: 20140370501
    Abstract: The present invention provides novel methods for determining the presence or amount of a hydrolytic enzyme in a sample, based on novel substrates for the enzymes, and also provides compositions and methods that provide highly sensitive assay methods for such hydrolytic enzymes.
    Type: Application
    Filed: June 19, 2014
    Publication date: December 18, 2014
    Inventors: Chong-Sheng YUAN, Xiaoru CHEN
  • Publication number: 20140370549
    Abstract: The disclosure provides a method of producing a scyllo-inositol or a new scyllo-inositol derivative in a one-step process, from ubiquitous and inexpensive raw materials. Also provided is a scyllo-inositol derivative bonded to saccharides such as glucose and similar.
    Type: Application
    Filed: January 22, 2013
    Publication date: December 18, 2014
    Applicant: ASAHI KASEI CHEMICALS CORPORATION
    Inventors: Kazunobu Konishi, Shinichi Imazu
  • Patent number: 8912165
    Abstract: A method of treating an ulcer comprising applying to the ulcer a preparation comprising a water-soluble ?-(1,3) glucan with ?-(1,6) linked side-chains, where the side-chains comprise ?-(1,3) linkages or up to four consecutive ?-(1,6) linkages a active ingredients.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: December 16, 2014
    Assignee: Biotec Pharmacon ASA
    Inventors: Rolf Engstad, Rolf Seljelid
  • Patent number: 8907070
    Abstract: Glycolipids of branched chain alkyl oligosaccharides include a primary alcohol branched in the 2-position and an oligosaccharide, covalently bond to the alcohol in either ?- or ?-linkage (shown in Formula I and Formula II). These compounds show phase behavior not found for the corresponding straight chain counterparts. The properties involve an ambient temperature liquid crystalline appearance and thermotropic liquid crystal phase polymorphism. The formation of cubic phases is considered most interesting with respect to life science applications, e.g. liposomes for drug delivery. Depending on the choice of sugar head group and alkyl tail, various levels of water miscibility may be adjusted to meet applications requirements (complete solubility for emulsifier applications, e.g. cosmetic creams, to limited water swelling only, e.g. for the preparation of artificial membranes).
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: December 9, 2014
    Assignee: Universiti Malaya
    Inventors: Rauzah Hashim, Thorsten Heidelberg, Hind Hassan, Nasrul Zamani Mohd Rodzi, Rusnah Syahila Dauli Hussen, Ahmad Sazali Hamzah, Shahidan Radiman, Volkmar Vill, Matthias Wulf, Seiji Ujiie
  • Patent number: 8889650
    Abstract: An antimelancholic pharmaceutical composition or health products prepared with jujuba cAMP materials and a preparative method are provided in the present invention. The present pharmaceutical composition includes jujuba cAMP as a solo effective ingredient for treating the depression. The present method for preparing the jujuba cAMP includes chromatographing a jujuba extract with a macroporous resin bound with an aldehyde group.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: November 18, 2014
    Assignees: Beijing Wonner Biotech, Ltd. Co.
    Inventor: Zuoguang Zhang
  • Publication number: 20140336136
    Abstract: The present invention relates to the use of certain stilbene derivatives for cosmetic and dermatological applications, in particular prevention and/or treatment of skin aging, as well as to cosmetic and dermatological compositions containing such stilbene derivatives.
    Type: Application
    Filed: May 7, 2014
    Publication date: November 13, 2014
    Applicant: RAHN AG
    Inventors: Jens Bitzer, Thomas Küper, Philipp Wabnitz